Status and phase
Conditions
Treatments
About
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients undergoing workup for suspected newly diagnosed sAA:
Marrow Cellularity: <25%, or 25-50% with <30% residual hematopoietic cells Peripheral cytopenias (at least 2 of 3) Absolute neutrophil count (ANC): <500 x 10^9/L Platelets: <20 x 10^9/L Absolute Reticulocyte Count: <60 x 10^9/L
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
55 participants in 2 patient groups
Loading...
Central trial contact
Jaap Jan Boelens, MD, PhD; Joseph Oved, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal